Scientists dive deep to unlock HPV Vaccine's lasting power
NCT ID NCT05031078
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 25 times
Summary
This study tracks 17 healthy adults aged 18-45 who receive the standard three-dose HPV vaccine. Researchers collect blood, saliva, lymph node, and bone marrow samples over five years to understand how the body builds and maintains strong antibody defenses. The goal is to learn why protection lasts so long, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Hope Clinic of Emory University
Atlanta, Georgia, 30030, United States
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.